HURA•prnewswire•December 9, 2025 at 02:49 PM

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

Summary

TAMPA, Fla., Dec. 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a definitive agreement for...

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on December 9, 2025 by prnewswire